Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25168320 | 1.00 | DDB1 (0.52) | DDB1CRBNHDAC8IKZF2 | |
| SCHEMBL25173024 | 1.00 | DDB1 (0.52) | DDB1CRBNHDAC8IKZF2 | |
| SCHEMBL28810518 | 0.90 | DDB1 (0.50) | DDB1CRBNHDAC8 | |
| SCHEMBL23301153 | 0.90 | DDB1 (0.50) | DDB1CRBNHDAC8 | |
| SCHEMBL28810174 | 0.89 | DDB1 (0.48) | DDB1CRBNHDAC8 | |
| SCHEMBL23302130 | 0.89 | DDB1 (0.48) | DDB1CRBNHDAC8 | |
| SCHEMBL23301296 | 0.87 | DDB1 (0.47) | DDB1CRBNHDAC8 | |
| SCHEMBL23551746 | 0.86 | DDB1 (0.64) | DDB1CRBN | |
| SCHEMBL23301551 | 0.86 | DDB1 (0.64) | DDB1CRBN | |
| SCHEMBL29744852 | 0.86 | DDB1 (0.64) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | DDB1 425/4885CRBN 32/4885HDAC8 459/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | DDB1 368/4885CRBN 249/4885HDAC8 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.